Literature DB >> 16787732

Photosensitized degradation of losartan potassium in an extemporaneous suspension formulation.

Randal A Seburg1, John M Ballard, Tsang-Lin Hwang, Caitlin M Sullivan.   

Abstract

During development of an extemporaneous suspension formulation for losartan potassium, previously unknown degradation products were observed in experimental suspensions prepared in a commercial cherry syrup vehicle. These degradates increased rapidly when analytical solutions prepared from that suspension were exposed to ambient light. The structures of the degradates were determined using a combination of preparative HPLC, LC/MS, (13)C and (1)H NMR (1D and 2D), and mechanistic chemistry. Each degradate results from destruction of the imidazole ring of losartan. Formation of the two major degradates required exposure to light (UV or visible) and the presence of oxygen. Experiments using Rose Bengal (a singlet oxygen photosensitizer) and 1,4-diazabicyclooctane (DABCO; a singlet oxygen quencher) established that the major photodegradates are formed via the intermediacy of singlet oxygen. The identity of the photosensitizer in the formulation was not unequivocally determined; however, the experiments implicated the artificial flavoring in fulfilling this role.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16787732     DOI: 10.1016/j.jpba.2006.04.030

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  1 in total

1.  Recent trends in product development and regulatory issues on impurities in active pharmaceutical ingredient (API) and drug products. Part 2: Safety considerations of impurities in pharmaceutical products and surveying the impurity landscape.

Authors:  Karen M Alsante; Kim C Huynh-Ba; Steven W Baertschi; Robert A Reed; Margaret S Landis; Scott Furness; Bernard Olsen; Mark Mowery; Karen Russo; Robert Iser; Gregory A Stephenson; Patrick Jansen
Journal:  AAPS PharmSciTech       Date:  2013-12-21       Impact factor: 3.246

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.